What the research shows
Investigators tested O304 in mice and in an early placebo-controlled study of adults with type 2 diabetes taking metformin. In a post hoc analysis of 49 participants, fasting glucose fell more over 28 days with O304 than with placebo. Within the O304 group, the estimated insulin resistance also decreased relative to baseline. That study did not measure long-term diabetes complications. Read the original O304 experiments and clinical results.
The developer describes the oral suspension used in the TELLUS trial and subsequent work on solid oral formulations. The code name connects those records. Read the developer’s formulation and trial history.
Documented formats
TELLUS evaluated an oral suspension. When comparing a tablet or capsule study, check which formulation the authors actually evaluated and whether they measured absorption.
Testing and purity
Look for the chemical identifier associated with O304 and an assay of the active compound. For a finished oral product, the strength per unit and the formulation also matter.
How to read a batch reportQuestions about ATX-304
Is ATX-304 a peptide?
Its active molecule is a small chemical compound. A peptide sequence is the wrong identifier for this material.
What is HOMA-IR in the paper?
It is an estimate calculated from fasting insulin and glucose. It gives researchers a way to compare insulin resistance across groups.